2022 ESMO大会即将于9月9日（欧洲中部夏令时间，CEST）在法国首都巴黎凡尔赛门展览馆开幕。
日前，含LBA在内的大会日程安排均已公布，「肿瘤资讯」整理了会上将进行报告的泌尿肿瘤研究，供参考。
Proffered Paper session & Presidential Symposium（按会议时间排序）
LBA4 ：辅助纳武利尤单抗加伊匹木单抗 vs. 安慰剂治疗肾切除术后复发风险高的局部肾细胞癌 ：随机III期 CheckMate 914 试验的结果
原标题：Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: results from the randomized, phase 3 CheckMate 914 trial
报告专家：Robert J. Motzer (New York, United States of America)
LBA8：卡博替尼（C）与纳武利尤单抗（N）和伊匹木单抗（I）联合治疗初治的IMDC中度或低风险晚期肾细胞癌 (aRCC) 的III期研究
原标题： Phase 3 study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)
报告专家：Toni K. Choueiri (Boston, United States of America)
LBA9 ：雄激素剥夺疗法与前列腺癌术后放疗的持续时间：RADIICS-HD 试验的初步结果
原标题： Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: first results of the RADICALS-HD trial (ISRCTN40814031)
报告专家：Chris C. Parker (Sutton, United Kingdom)
LBA66 ：IMmotion010 III期研究：在手术切除术后复发风险增加的肾细胞癌患者中比较阿替利珠单抗vs.安慰剂作为辅助治疗的疗效和安全性
原标题： IMmotion010: efficacy and safety from the Phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection
报告专家：Axel Bex (London, United Kingdom)
LBA67 ：在接受肾切除术的肾细胞癌患者中进行围手术期纳武利尤单抗治疗与观察等待结果对比，一项国家临床试验网络试验的 III 期随机化研究(PROSPER，ECOG-ACRIN EA8143)
原标题： Phase III RandOmized Study Comparing PErioperative Nivolumab (nivo) versus Observation in Patients (Pts) with Renal Cell Carcinoma (RCC) Undergoing Nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial
报告专家：Mohamad Allaf (Boston, United States of America)
LBA74 ： JAVELIN Bladder 100 试验——用于预测avelumab一线维持治疗的晚期尿路上皮癌患者外周血中的基因组生物标志物
原标题：Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)
报告专家：Thomas B. Powles (London, United Kingdom)
LBA68 ：Bempegaldesleukin联合纳武利尤单抗 vs. 研究人员选择的舒尼替尼或卡博替尼治疗初治晚期肾细胞癌：III期随机研究(PIVOT-09)的结果
原标题： Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the investigator’s choice of Sunitinib or Cabozantinib in previously untreated advanced renal cell carcinoma (RCC): Results from a Phase 3 randomized study (PIVOT-09)
报告专家：Nizar Tannir (Houston, United States of America)
LBA73 ：EV-103 Cohort K研究：enfortumab vedotin单药治疗或与帕博利珠单抗联合治疗先前未治疗的不宜顺铂治疗的局部晚期或转移性尿路上皮癌患者的抗肿瘤活性
原标题： Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)
报告专家：Jonathan E. Rosenberg (New York, United States of America)
LBA62：在初始雄激素剥夺治疗的转移性激素敏感性前列腺癌患者中比较醋酸阿比特龙+泼尼松龙与恩扎卢胺+醋酸阿比特龙+泼尼松龙联合治疗的疗效：STAMPEDE方案中2项 III 期随机试验的总生存期结果
原标题： Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): overall survival (OS) results of 2 randomised Phase III trials from the STAMPEDE protocol
报告专家：Gerhardt Attard (London, United Kingdom)
LBA63 :PRESTO：一项在高危生化复发性前列腺癌 (AFT-19) 患者中评价雄激素阻断的 III 期、开放性研究
原标题： PRESTO: A Phase 3, Open-Label Study of Androgen Annihilation in Patients (pts) with High-Risk Biochemically Relapsed Prostate Cancer (AFT-19)
报告专家：Rahul Aggarwal (San Francisco, United States of America)
Mini Oral session
LBA64 ：术后放疗的雄激素抑制持续时间 (DADSPORT)：综合数据的荟萃分析
原标题： Duration of androgen suppression with post-operative radiotherapy (DADSPORT): A collaborative meta-analysis of aggregate data
报告专家：Sarah Burdett (London, United Kingdom)
LBA65 ： SAKK 08/14 - IMPROVE：比较二甲双胍联合恩扎卢胺 vs. 恩扎卢胺单药治疗转移性去势抵抗性前列腺癌，一项随机、开放性、II期试验
原标题： SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial
报告专家：Christian A. Rothermundt (St. Gallen, Switzerland)
LBA75 ：
RACE IT——前瞻性、单组、多中心、II期试验的首次结果：评估局部晚期膀胱尿路上皮癌 (AB 65/18) 根治性膀胱切除术前 RAdiation 治疗联合免疫治疗的安全性和疗效
原标题： RACE IT - A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18) – first results
报告专家：Sebastian C. Schmid (Munich, Germany)
LBA69 ：Belzutifan，一种 HIF-2α 抑制剂，用于治疗 von Hippel-Lindau疾病相关肿瘤：随访36 个月的LITESPARK-004 II期研究
原标题： Belzutifan, a HIF-2α Inhibitor, for von Hippel-Lindau (VHL) Disease–Associated Neoplasms: 36 Months of Follow-Up of the Phase 2 LITESPARK-004 Study
报告专家：Ramaprasad Srinivasan (Bethesda, United States of America)
排版编辑：肿瘤资讯-LH
苏公网安备32059002004080号
